Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2018

View Archived Issues

FDA grants orphan drug designation to BN-Brachyury as treatment for chordoma

Refuge Biotechnologies completes series B financing

Azitra raises new financing to advance pipeline

Coherus BioSciences announces re-submission of BLA for CHS-1701

Daiichi Sankyo profiles highlights of fourth quarter of fiscal 2017

Abbisko presents novel candidates with promising preclinical profiles

Phase I results reported for analgesic CCR2 antagonist CNTX-6970

RBH-61, a dual SEH/PDE inhibitor for inflammatory pain

FDA grants two fast track designations for 5F9

Ocular Therapeutix doses first patient in phase I clinical trial of OTX-TIC

Bristol-Myers Squibb presents new apelin receptor agonists

Ferring Pharmaceuticals acquires option to commercialize nadofaragene firadenovec/Syn3

AbbVie divulges novel BRD4 inhibitors

Jiangsu Hengrui Medicine and collaborator disclose TGFR-1 inhibitors

Sanofi reviews key events of first quarter 2018

Phase III trial of ranibizumab biosimilar FYB-201 meets primary endpoint

RTI International discovers new APLNR agonists

Dong-A Socio Holdings identifies Mer inhibitors

Phase I trial begins of CS-1002 for advanced solid tumors begins in Australia

FDA joint advisory committee meeting recommends against stannsoporfin

Moderna Therapeutics and Merck & Co. expand cancer collaboration

New albumin-binding compounds from CytRx show antitumor activity in xenograft models

FDA approves AndexXa to reverse factor Xa inhibitors

Altum Pharmaceuticals acquires Lexi Pharma

First patient dosed in phase II study of AG-10 in ATTR cardiomyopathy

DLK inhibitor shows promising data in vivo

Casma Therapeutics launched to develop breakthrough therapies by boosting autophagy

OTL-200 receives rare pediatric disease designation from the FDA

EMA validates type II variation application for Opdivo plus Yervoy in first-line NSCLC

Sarepta partners with Myonexus to advance gene therapies for limb-girdle muscular dystrophy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...